Substance Use Tools & Resources
This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 [PDF 0.69 MB] and Volume 2 [PDF 1.28 MB] of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.
Displaying 51 - 60 of 946
This case study explores implementation of medications for opioid use disorder (MOUD) at a federally qualified health center (FQHC) in rural California that engages with the broader community to address the opioid epidemic.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Policymakers and Payers
Source
Centers for Health Care Strategies (CHCS)
Year
Resource Type
PDF
Embracing Equity and Cultural Humility to Improve Care for Youth with Trauma
This resource provides information for youth-serving primary care and behavioral health providers to improve quality of care and patient outcomes and reduce clinician burnout
Format
Guide
Audience
Behavioral Health Providers
Schools
Communities
Other Team Members
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF
Engagement and Retention of Nonabstinent Patients in Substance Use Treatment
This document was developed to provide SUD treatment programs and providers with guidance and support to: 1) address the complexities of patient nonabstinence during treatment; 2) reduce administrative discharges; and 3) implement strategies focused on lowering barriers to care to improve engagement and retention of nonabstinent patients in the continuum of care.
Format
Guide
Audience
Behavioral Health Providers
Other Team Members
Communities
Source
American Society of Addiction Medicine
Year
Resource Type
PDF
Engaging PWLEE in Overdose Data Collection, Interpretation and Dissemination
This tool highlights examples of successful People With Lived or Living Experience (PWLLE) engagement in data collection, interpretation and dissemination, as well as novel approaches to community-based participatory research, such as patient journey mapping and PWUD/researcher collectives. It also includes key considerations for gathering and disseminating data. The target audience for this tool includes the staff of epidemiology and surveillance departments.
Format
Report/Paper/Issue Brief
Audience
Graduate Education
Other Team Members
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF
Engaging PWLLE in Overdose Data Collection, Interpretation and Dissemination
This tool highlights examples of successful People With Lived and Living Experience (PWLLE) engagement in data collection, interpretation and dissemination, gathered through key informant interviews — including overdose fatality review committees, drug checking, patient surveys and overdose reversal reporting — as well as novel approaches to community-based participatory research.
Format
Report/Paper/Issue Brief
Audience
States
Communities
Other Team Members
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF
FAQs on Medicaid and CHIP Coverage of Peer Support Services Available from CMS
These FAQs provide clarification regarding federal policy on coverage of peer support services.
Format
Other
Audience
Policymakers and Payers
States
Source
Centers for Medicare & Medicaid Services (CMS)
Year
Resource Type
PDF
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
The article discusses the new FDA approval for the first nalmefene hydrochloride auto-injector for emergent treatment of a suspected opioid overdose.
Format
Advisory
Audience
Medical Providers
First Responders
Source
U.S. Food and Drug Administration (FDA)
Year
Resource Type
Web Page
FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder
This press release details the FDA's recommended changes to labeling transmucosal buprenorphine products for opioid use disorder treatment. These recommendations are motivated by concerns about misinterpretation about current labeling strategies.
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Source
U.S. Food & Drug Administration (FDA)
Year
Resource Type
Web Page
Financing the Future of Integrated Care: Medications for Opioid Use Disorder
This brief is part of a series that aims to accelerate the ease of implementation of evidence-based integrated care interventions across a myriad of organization settings. It provides practical guidance on MOUD financing strategies.
Format
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Medical Providers
Other Team Members
Communities
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF
Financing the Future of Integrated Care: Screening in Behavioral Health and Primary Care Settings
This brief is part of a series that aims to accelerate implementation of evidence-based integrated care interventions across a myriad of organization settings. It aims to highlight considerations salient to the aim of cross pollinating screenings in mental health and substance use and primary care settings.
Format
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Medical Providers
Other Team Members
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF